Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies.

Freites-Martinez, ASantana, NArias-Santiago, SViera, A2023-02-092023-02-092020-09-03http://hdl.handle.net/10668/16214enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Adverse Drug Reaction Reporting SystemsNational Cancer Institute (U.S.)United StatesUsing the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies.CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas.research article32891586open access10.1016/j.ad.2019.05.0092173-5778https://doi.org/10.1016/j.ad.2019.05.009